Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors
2026（225）
Phase 2 small_molecule active
Quick answer
Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors for Cancer of Biliary Duct is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Cancer of Biliary Duct
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active